Interestingly, the CD33_PGx6_Score—a composite score derived from six CD33 SNP of prognostic significance (rs12459419, rs2455069, rs201074739, rs35112940, rs61736475 and rs1803254)—has been recently set up to assess the impact of CD33 genotype on CD33 expression and GO response among 938 patients with de novo AML, aged 0–29 years [116]. The gene discussed is CD33; the disease is acute myeloid leukemia.